The outlook of companies tied to Viagra's history presents a intricate investment scenario . While the initial surge generated substantial gains, generic competition have significantly eroded sales . Investing in related pharmaceutical firms now requires a careful assessment of proprietary safeguards, evolving patient trends , and the possibility f